PFS
FIGURE 1 · Panel A
Panel A 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Per Olsson Gisleskog, Belén Valenzuela, Nicoline Treijtel, Sanjay Deshpande, Todd Henninger, Juan José Perez-Ruixo
CPT Pharmacometrics Syst Pharmacol 14(10) 1562-1574
Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE). The analysis described explores the ibrutinib population pharmacokinetics (PK) and exposure-response (E-R) relationships of selected efficacy and safety endpoints. Ibrutinib PK was consistent with previous assessments, characterized by an open two-compartment disposition model with sequential zero-first order oral absorption after a lag time. Ibrutinib treatment was efficacious in extending PFS versus placebo (HR: 0.75; 95% CI: 0.59 to 0.96), although similar OS, CRR, and ORR were observed. PFS benefit was similar across the quartiles of ibrutinib exposure, suggesting that systemic exposures obtained provide maximal clinical response. There was no association between ibrutinib exposure and incidence of major hemorrhage, Grade ≥ 3 liver function test abnormalities, Grade ≥ 3 neutropenia, Grade ≥ 2 diarrhea, treatment-emergent adverse events (TEAEs) leading to death, and TEAEs leading to ibrutinib dose reduction. However, the incidence of all Grade ≥ 3 TEAEs, all serious TEAEs, TEAEs leading to ibrutinib discontinuation, Grade ≥ 1 atrial fibrillation, any hemorrhage, and Grade ≥ 3 infection was higher in the ibrutinib than placebo arm. Of these, only atrial fibrillation and any hemorrhage increased with increasing exposure. Overall, ibrutinib 560 mg, combined with BR, consistently improves PFS across the ibrutinib exposure range evaluated. According to the results of the exposure-response analysis, for patients who develop specific toxicities, dose reduction according to the prescribing information may improve the ibrutinib tolerability while keeping adequate exposure to maintain efficacy.
1 个 Figure · 2 个 KM 面板
FIGURE 1 Kaplan–Meier plots of PFS (A) and OS (B) stratified by quartiles of ibrutinib AUC τ,ss and efficacy response rates by quartiles of ibrutinib AUC τ,ss (C). Dots show different efficacy endpoint incidences (and 95% CI) at the median ibrutinib AUC t,ss for each ibrutinib AUC t,ss quartile. Dashed lines show the boundaries of the quartiles. Horizontal lines show incidence in placebo arm (black), and the associated 95% CI (gray). [Correction added on 10 July 2025, after first online publication: Resolution for Figure 1 has been updated in this version.]
FIGURE 1 · Panel A
Panel A 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 1 · Panel B
Panel B 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。